SpineJack trial results lead to European launch
This article was originally published in Clinica
The European launch of SpineJack, Vexim's vertebral implant, is expected "within the next few weeks" following positive clinical trial results. The titanium implant, designed for minimally-invasive anatomical restoration of vertebral compression fractures, has been proven efficacious in two clinical studies in a total of 120 patients. Following implantation of the SpineJack, all patients experienced rapid pain relief and correction of post-trauma deformation, assessed by methods including conventional radiography and CT scanning. Vexim (Toulouse, France) CE marked SpineJack in May 2008, but decided to market it only after demonstrating its efficacy in international clinical trials. SpineJack is inserted into a patient's vertebra via a transpedicular approach, involving the X-ray-guided insertion of one or two implants, depending on the anatomical configuration of the fracture and the degree of reconstruction required. The company is planning to conduct further clinical studies of SpineJack this year.